New research reveals that people who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional lifestyle plans.
Findings released in a leading medical journal demonstrates that while overweight individuals can lose substantial amounts of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals buying these drugs need to be cognizant of the danger of quick rebound weight gain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to starting mass within about a year and a half.
Comparing Therapies
The study, which reviewed dozens of studies involving thousands of participants, contrasted the outcomes of the injectable medications with other pills.
Researchers emphasize that individuals who lose weight through dieting typically experience a slower weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors propose the mechanism of the drugs is key to understanding the amplified rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making excessive eating far more likely."
A Chronic Disease?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, due to the likelihood of weight regain, the therapy is often ongoing.
This opinion is reinforced by drug manufacturers, who note that the findings "underscore the long-term nature of excess weight," akin to managing conditions like hypertension.
User Accounts
Users who have discontinued the medication describe a sudden resurgence of cravings.
"I experienced something activating and you become starving," described a patient.
This difficulty is exacerbated if patients have not adopted permanent lifestyle or habit changes during treatment.
Widespread Use
Recent estimates suggest that a significant number of people in the UK have tried these injections in the past year, with demand continuing to grow.
- Use is higher among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, researchers emphasize that while the jabs are potent tools for weight loss, they are not a magic fix and long-term success hinges on combined behavioural management.
